---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-016076"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2023-09-27T23:59:59+00:00"
generated_at: "2026-06-10T08:05:40.308719+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aytu Q4 record revenue $30.7M, positive Adj. EBITDA $7.7M, prescriptions up 32%

## Summary
- Q4 net revenue $30.7M (+12% YoY); Rx segment $23.3M (+24%); total prescriptions 155,562 (+32%).
- Net loss improved to $2.5M ($0.59/share) from $16.1M ($8.95/share) a year ago; $0.6M net income excluding impairment.
- Adjusted EBITDA positive $7.7M in Q4 vs negative $3.9M; FY23 Adj. EBITDA positive $3.2M vs negative $21.5M.
- Cash ended at $23.0M, up from $19.2M in March; company plans to monetize or discontinue Consumer Health segment.
- Gross margin improved to 60% (Q4) and 62% (FY) from 54% in both prior-year periods.

## SEC filing metadata
- accession: 0001558370-23-016076
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2023-09-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000155837023016076/0001558370-23-016076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000155837023016076/aytu-20230927x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-016076
- JSON: https://secwatch.observer/filing/0001558370-23-016076.json
- Plain text: https://secwatch.observer/filing/0001558370-23-016076.txt

## Key facts
- Earnings Releases
  AYTU BIOPHARMA, INC reported the fiscal quarter ended June 30, 2023 results: revenue $30.7 million, net income $2.5 million, EPS $0.59 per share.
  - Period: the fiscal quarter ended June 30, 2023
  - Revenue: $30.7 million
  - Net income: $2.5 million
  - EPS: $0.59 per share
  - Result: reported results
  source text: BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023 Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 million Record Q4 2023 total prescriptions increased 32% compared to Q4 2022 Rx Segment net revenue of $23.3 million and Adjusted EBITDA of $8.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000155837023016076/0001558370-23-016076-index.htm
- Earnings Releases
  AYTU BIOPHARMA, INC reported the fiscal year ended June 30, 2023 results: revenue $107.4 million, net income $17.1 million, EPS $5.11 per share.
  - Period: the fiscal year ended June 30, 2023
  - Revenue: $107.4 million
  - Net income: $17.1 million
  - EPS: $5.11 per share
  - Result: reported results
  source text: were $23.0 million at June 30, 2023 compared to $19.2 million at March 31, 2023. ​ FY 2023 Commercial Highlights (12 months ending June 30, 2023) ● Total net revenue was $107.4 million, an increase of 11% from $96.7 million in net revenue in FY 2022. ● Net revenue from the Company’s Rx segment was $73.8 million during FY 2023 compared to $61.1 million in FY
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000155837023016076/0001558370-23-016076-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.